Analyzing clinical characteristics of severe anthrax patients and their survival rates
A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
Tongji Hospital · NCT06365073
This study looks at the health details of people with severe anthrax to see what helps them survive after being treated in the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tongji Hospital (other) |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06365073 on ClinicalTrials.gov |
What this trial studies
This observational study examines the clinical characteristics of patients diagnosed with severe anthrax, focusing on those who survived for 28 days and 90 days post-discharge. It is a multi-center, retrospective case-control study that collects data on vital signs, blood tests, and therapeutic interventions during hospitalization. The study aims to identify factors associated with survival and the impact of multiple organ dysfunction on patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with severe anthrax exhibiting multiple organ dysfunction.
Not a fit: Patients with other conditions affecting short-term survival may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of severe anthrax and improve treatment strategies for affected patients.
How similar studies have performed: While there have been studies on anthrax, this specific case-control approach focusing on survival characteristics is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The typical bacilli with capsules were found in smear examination and culture of various secretions, excretions, blood and cerebrospinal fluid. 2. Multiple organ dysfunction (MODS) in brain, heart, liver, kidney, coagulation or more than one organ failure. Exclusion Criteria: There are other conditions that affect short-term survival.
Where this trial is running
Wuhan, Hubei
- Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (RECRUITING)
Study contacts
- Study coordinator: Qin Ning, professor
- Email: qning@vip.sina.com
- Phone: 027-83665919
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Anthrax